BC Extra | Aug 21, 2018
Company News

Management tracks: HBP parts ways with Executive Director Chris Ebell

The Human Brain Project (HBP) said Executive Director and Head of the Project Coordination Office Chris Ebell has resigned "following a change of university leadership and differences of opinion on governance and on strategic orientations...
BC Extra | May 29, 2018
Company News

Management tracks: Axovant, Revance

Axovant Sciences Ltd. (NASDAQ:AXON) hired Gavin Corcoran as EVP of R&D and appointed Michael Hayden as senior scientific advisor and chairman of the neurology company’s new scientific advisory board as part of an ongoing restructuring....
BC Extra | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...
BC Extra | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Sep 29, 2017
Financial News

Ascendis and Catalent price follow-ons

Catalent Inc. (NYSE:CTLT) and Ascendis Pharma A/S (NASDAQ:ASND) each priced follow-on offerings, raising more than $380 million. Ascendis raised $134.9 million on Sept. 27 through the sale of 3.8 million ADSs at $35.50 in a...
BC Extra | Sep 27, 2017
Financial News

Follow-on roundup: Ascendis, Catalent

Ascendis Pharma A/S (NASDAQ:ASND) and Catalent Inc. (NYSE:CTLT) each priced follow-on offerings, raising more than $380 million. Ascendis raised $134.9 million on Wednesday through the sale of 3.8 million ADSs at $35.50 in a follow-on...
BC Extra | Sep 22, 2017
Financial News

Versartis plummets on Phase III GHD miss

Versartis Inc. (NASDAQ:VSAR) lost $18.93 (88%) to $2.67 on Friday after announcing after market close Thursday that somavaratan (VRS-317) missed the primary endpoint in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency...
BC Week In Review | Sep 22, 2017
Clinical News

Versartis' somavaratan misses in Phase III for pediatric GHD

Versartis Inc. (NASDAQ:VSAR) said somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency (GHD). In the intent-to-treat (ITT) population, twice-monthly subcutaneous...
Items per page:
1 - 10 of 92
BC Extra | Aug 21, 2018
Company News

Management tracks: HBP parts ways with Executive Director Chris Ebell

The Human Brain Project (HBP) said Executive Director and Head of the Project Coordination Office Chris Ebell has resigned "following a change of university leadership and differences of opinion on governance and on strategic orientations...
BC Extra | May 29, 2018
Company News

Management tracks: Axovant, Revance

Axovant Sciences Ltd. (NASDAQ:AXON) hired Gavin Corcoran as EVP of R&D and appointed Michael Hayden as senior scientific advisor and chairman of the neurology company’s new scientific advisory board as part of an ongoing restructuring....
BC Extra | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...
BC Extra | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Sep 29, 2017
Financial News

Ascendis and Catalent price follow-ons

Catalent Inc. (NYSE:CTLT) and Ascendis Pharma A/S (NASDAQ:ASND) each priced follow-on offerings, raising more than $380 million. Ascendis raised $134.9 million on Sept. 27 through the sale of 3.8 million ADSs at $35.50 in a...
BC Extra | Sep 27, 2017
Financial News

Follow-on roundup: Ascendis, Catalent

Ascendis Pharma A/S (NASDAQ:ASND) and Catalent Inc. (NYSE:CTLT) each priced follow-on offerings, raising more than $380 million. Ascendis raised $134.9 million on Wednesday through the sale of 3.8 million ADSs at $35.50 in a follow-on...
BC Extra | Sep 22, 2017
Financial News

Versartis plummets on Phase III GHD miss

Versartis Inc. (NASDAQ:VSAR) lost $18.93 (88%) to $2.67 on Friday after announcing after market close Thursday that somavaratan (VRS-317) missed the primary endpoint in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency...
BC Week In Review | Sep 22, 2017
Clinical News

Versartis' somavaratan misses in Phase III for pediatric GHD

Versartis Inc. (NASDAQ:VSAR) said somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency (GHD). In the intent-to-treat (ITT) population, twice-monthly subcutaneous...
Items per page:
1 - 10 of 92